Word on the Street
"This is clinical development so there are going to be some setbacks."
– Gil Van Bokkelen, CEO of Athersys Inc. and chairman of the Alliance for Regenerative Medicine
"You can see a slight change in subject one's pulse here. But I can tell you, his pulse was substantially lower than my own pulse when this vector was going in."
– Amit Nathwani, investigator on a trial testing Factor IX gene therapy for hemophilia B, describing monitoring patients for adverse reaction during infusions
"If programs stumble, jobs are at stake."
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST